Gül, A. Et Al. 2017. A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects. ARTHRITIS & RHEUMATOLOGY , vol.69 .

Gül, A., Ulker, S., Senturk, R. S., Turk, U. O., GÜRGÜN, C., Lavrovsky, Y., ... Samsonov, M.(2017). A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects. ARTHRITIS & RHEUMATOLOGY , vol.69.

Gül, Ahmet Et Al. "A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects," ARTHRITIS & RHEUMATOLOGY , vol.69, 2017

Gül, Ahmet Et Al. "A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects." ARTHRITIS & RHEUMATOLOGY , vol.69, 2017

Gül, A. Et Al. (2017) . "A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects." ARTHRITIS & RHEUMATOLOGY , vol.69.

@article{article, author={Ahmet GÜL Et Al. }, title={A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects}, journal={ARTHRITIS & RHEUMATOLOGY}, year=2017}